H.C. Wainwright analyst Arthur He initiated coverage of Poseida Therapeutics with a Buy rating and $15 price target. Poseida is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies to treat cancers and rare genetic diseases, He tells investors in a research note. The analyst says the company’s PiggyBac and Cas-CLOVER technology can unlock the potential of CAR-T treatment.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PSTX:
- Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks
- Poseida presents preclinical data from P-FVIII-101 gene therapy for hemophilia A
- Poseida Therapeutics reports Q3 EPS 92c, consensus (65c)
- Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
